Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9Bn By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.
You may also be interested in...
Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. And London-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.